FMP
Satsuma Pharmaceuticals, Inc.
STSA
NASDAQ
Inactive Equity
Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. The company's lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in SUMMIT Phase 3 efficacy trials and can be self-administered with proprietary pre-filled, single-use, and nasal delivery device. Satsuma Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
1.1 USD
0 (0%)
About
ceo
Mr. John A. Kollins MBA
sector
Healthcare
industry
Biotechnology
website
https://www.satsumarx.comexchange
NASDAQ
Description
Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. The company's lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in SUMMIT Phase 3 efficacy trials and can be self-administered with proprietary pre-filled, single-use, and nasal delivery device. Satsuma Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
CIK
0001692830
ISIN
US80405P1075
CUSIP
80405P107
Address
400 Oyster Point Boulevard
Phone
650 410 3200
Country
US
Employee
25
IPO Date
Sep 13, 2019
Key Executives
